Cite
HARVARD Citation
Leiba, M. et al. (n.d.). Bortezomib‐Cyclophosphamide‐Dexamethasone (VCD) versus Bortezomib‐Thalidomide‐Dexamethasone (VTD) ‐based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta‐analysis. British journal of haematology. pp. 702-710. [Online].